These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18224680)

  • 1. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6.
    Ueda R; Kinoshita E; Ito R; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2008 May; 122(10):2274-9. PubMed ID: 18224680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
    Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a human glioma antigen, SOX6, recognized by patients' sera.
    Ueda R; Iizuka Y; Yoshida K; Kawase T; Kawakami Y; Toda M
    Oncogene; 2004 Feb; 23(7):1420-7. PubMed ID: 14691456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model.
    Ahn E; Kim H; Han KT; Sin JI
    Cancer Lett; 2015 Jan; 356(2 Pt B):676-85. PubMed ID: 25449428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
    Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
    Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage.
    Zheng J; Liu P; Yang X
    Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):1006-14. PubMed ID: 23169344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
    Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
    Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
    Ji H; Wang TL; Chen CH; Pai SI; Hung CF; Lin KY; Kurman RJ; Pardoll DM; Wu TC
    Hum Gene Ther; 1999 Nov; 10(17):2727-40. PubMed ID: 10584920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
    J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.
    Qian J; Zheng Y; Zheng C; Wang L; Qin H; Hong S; Li H; Lu Y; He J; Yang J; Neelapu S; Kwak LW; Hou J; Yi Q
    Blood; 2012 Jan; 119(1):161-9. PubMed ID: 22049519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.
    Wang XY; Kazim L; Repasky EA; Subjeck JR
    Int J Cancer; 2003 Jun; 105(2):226-31. PubMed ID: 12673684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA.
    Yamanaka R; Yajima N; Tsuchiya N; Honma J; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG
    J Neurosurg; 2002 Nov; 97(5):1184-90. PubMed ID: 12450042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.